Tuesday, January 7, 2014

Seeking Alpha: Kinect-2 Puts '854 Back Into Play For Neurocrine

Tuesday is going to be a good day for Neurocrine Biosciences (NBIX) and its shareholders. Strong data from the Phase IIb Kinect-2 study of NBI-98854 ('854) in tardive dyskinesia surprised the Street in a big way, and the shares are poised to jump as a potentially valuable drug suddenly looks much more viable than just a few months ago.

When it comes to the stock market and clinical trial data coming out of biotechs, the reactions often remind me of a cat chasing a laser pointer. Keep that in mind when contemplating the ultimate odds of approval and the challenges in designing a Phase III study that will not only cast the drug in the best light, but also satisfy the FDA's demands. I'm still bullish on Neurocrine and still a shareholder myself, but I'm not increasing my estimated fair value on the shares nearly as much as the Street appears poised to in pre-market trading.

Click on this link to read more:
Kinect-2 Puts '854 Back Into Play For Neurocrine

No comments: